Table 3.

The three- and five-year overall survival and event free survival of conventional staging and metabolic staging in initial staging of hodgkin lymphoma patients

Survival	150 Patients CS	117 Patients MS	267 Total patients
Three-year EFS
Stage I	91.7%	100.0%	93.7%
Stage II	78.7%	84.4%	80.9%
Early stage	80.7%	85.6%	82.6%
Stage III	79.7%	76.7%	78.4%
Stage IV	63.7%	65.2%	64.5%
Advanced stage	71.0%	70.0%	70.5%
Five-year EFS
Stage I	91.7%	100.0%	93.7%
Stage II	77.0%	84.4%	79.8%
Early stage	79.3%	85.6%	81.5%
Stage III	76.5%	69.0%	73.1%
Stage IV	58.6%	44.8%	53.7%
Advanced stage	66.7%	53.6%	61.9%
Three-year OS
Stage I	91.7%	100.0%	93.7%
Stage II	93.2%	97.2%	94.8%
Early stage	93.0%	97.5%	94.6%
Stage III	94.2%	96.3%	95.2%
Stage IV	77.2%	74.2%	75.7%
Advanced stage	84.9%	82.8%	83.9%
Five-year OS
Stage I	91.7%	100.0%	93.7%
Stage II	91.2%	97.2%	93.3%
Early stage	91.3%	97.5%	93.4%
Stage III	94.2%	90.9%	92.9%
Stage IV	71.1%	74.2%	72.5%
Advanced stage	81.5%	80.7%	81.1%

OS: Overall survival; EFS: Event free survival; CS: Conventional stage; MS: Metabolic staging.